Butterfly, Graham, Wise Equity target nutraceuticals; Demand for antimicrobial testing drives Astorg’s $1bn carve-out of Thermo Fishers’ microbiology biz
Butterfly Equity, Graham Partners and Wise Equity are among the firms transacting with nutraceuticals assets. The post Butterfly, Graham, Wise Equity target nutraceuticals; Demand for antimicrobial testing drives Astorg’s $1bn carve-out of Thermo Fishers’ microbiology biz…
Butterfly Equity, Graham Partners and Wise Equity are among the firms transacting with nutraceuticals assets. The post Butterfly, Graham, Wise Equity target nutraceuticals; Demand for antimicrobial testing drives Astorg’s $1bn carve-out of Thermo Fishers’ microbiology biz…
BELLINGS Intelligence Score: 18
Why it matters
This event describes private equity firms targeting nutraceuticals and a $1bn carve-out deal in microbiology, representing notable but routine private-market activity with limited systemic or market-wide impact.
Sources
PE Hub
Butterfly, Graham, Wise Equity target nutraceuticals; Demand for antimicrobial testing drives Astorg’s $1bn carve-out of Thermo Fishers’ microbiology biz
Butterfly Equity, Graham Partners and Wise Equity are among the firms transacting with nutraceuticals assets. The post Butterfly, Graham, Wise Equity target nutraceuticals; Demand for antimicrobial testing drives Astorg’s $1bn carve-out of Thermo Fishers’ microbiology biz…